BMY
Bristol-Myers Squibb Company
BMY has lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over BMY overall, supported by stronger fundamentals and stronger modeled upside.
BMY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Stable |
BMY's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BMY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.7x | $62.32 | — |
| Cheap | 14x | $65.37 | +4.9% |
| Current | 14x | $62.32 | — |
| Fair | 18x | $83.24 | +34% |
| Expensive | 25x | $114 | +83% |
Historical ranges are pointers, not guarantees.
BMY has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BMY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect BMY's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BMY on the outlook, with more favorable revenue expectations.
BMY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.45 | +43% |
| Q3 2026 | $4.52 | +52% |
| Q2 2026 | $4.55 | +83% |
| Q1 2026 | $3.57 | +33% |
| Q4 2025 | $3.46 | +$7.87 |
| Q3 2025 | $2.97 | +$6.56 |
| Q2 2025 | $2.49 | +$5.75 |
| Q1 2025 | $2.68 | +$5.78 |
| Q4 2024 | -$4.41 | -214% |
BMY earned $4.52 per share over the past year, up 52% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BMY on earnings, with more consistent year-over-year improvement.
BMY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.1B | +6.9% |
| Q2 2026 | $13B | +5.7% |
| Q1 2026 | $11.5B | +2.6% |
| Q4 2025 | $12.5B | +1.3% |
| Q3 2025 | $12.2B | +2.8% |
| Q2 2025 | $12.3B | +0.6% |
| Q1 2025 | $11.2B | -5.6% |
| Q4 2024 | $12.3B | +7.5% |
BMY's revenue has grown year over year for six quarters in a row: $13.1B last quarter, up 6.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | -6.1 points |
| Q2 2026 | 32% | +17 points |
| Q1 2026 | 28% | +1.7 points |
| Q4 2025 | 12% | +10 points |
| Q3 2025 | 25% | +11 points |
| Q2 2025 | 14% | +3.9 points |
| Q1 2025 | 27% | +124 points |
| Q4 2024 | 1.4% | -13 points |
BMY's operating margin was 19% last quarter, down 6.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BMY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BMY on profitability, with a higher operating margin.
BMY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.8B | -36% |
| Q2 2026 | $3.1B | -13% |
| Q1 2026 | $757M | -55% |
| Q4 2025 | $1.6B | -61% |
| Q3 2025 | $6B | +14% |
| Q2 2025 | $3.6B | +72% |
| Q1 2025 | $1.7B | -34% |
| Q4 2024 | $4.1B | +3.5% |
BMY's free cash flow has been positive every quarter for seven years: $9.3B over the past year, down 39% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BMY on cash flow, with more consistent year-over-year improvement.
BMY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +5M shares |
| 1 year | +0.7% | +14M shares |
| 3 years | -0.5% | -11M shares |
| 5 years | -8.5% | -190M shares |
| Available history | -9.1% | -205M shares |
BMY has 2.1B diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $4B |
| Q2 2023 | $905M |
| Q1 2023 | $250M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BMY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BMY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 32.2x | High |
BMY's net debt is about 2.4 years of its operating earnings (EBITDA), down from 2.6 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over BMY on leverage, with a lower net debt burden relative to earnings.
BMY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.7 | Neutral |
| Stochastic | 49.4 | Neutral |
BMY's weekly RSI is 54 (neutral) and its Stochastic is 49 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BMY PE vs Healthcare Sector
| Metric | BMY | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 47% below |
| PE % | 12 | 29 | 17 pts below |
BMY has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BMY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 1.5% above |
| 20 week MA | $62.5 | 0.4% below |
| 50 week MA | $59.4 | 4.9% above |
| 100 week MA | $54.9 | 13% above |
| 200 week MA | $55.4 | 13% above |
BMY's trend is mixed: it's above four of its five weekly moving averages, and 13% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BMY on trend strength, trading above more of its moving averages.
BMY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $64.1 | $61.2 | -4.7% |
| 2021 | $61.2 | $62.1 | +1.5% |
| 2022 | $62.1 | $72.9 | +17% |
| 2023 | $72.9 | $51.3 | -30% |
| 2024 | $51.3 | $57.7 | +12% |
| 2025 | $57.7 | $54.6 | -5.3% |
| 2026 YTD | $54.6 | $62.3 | +14% |
BMY has finished lower in three of the last six years. It's up 14% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BMY on returns for 2026, with the stronger performance.